Amneal Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
Business Address , , ,
Mailing Address 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807
Phone (908) 947-3120
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
$3.50B
Total Assets
$-0.48
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | November 19, 2025 | View on SEC |
| 4 Insider stock transaction report | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 6, 2025 | View on SEC |
| 8-K Current report of material events | October 30, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | October 7, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | October 6, 2025 | View on SEC |
| 4 Insider stock transaction report | August 28, 2025 | View on SEC |
Material Events
8-K Legal Issue January 28, 2026
High Impact
- Finalized nationwide opioid settlement resolves major legal uncertainty and provides legal certainty.
- Settlement reduces risk of unpredictable legal judgments and high defense costs, allowing management to focus on core business.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.